This was an OK quarter. A lot of posted comments on "window-dressing", but truth is - any CEO right now is a fool to let on too much. They got the job done. Revenues rose at previously stated target, and expenses were kept pretty flat. The cash did not earn much - well, neither did my linked money market to stock account. For a small company, KOOL is doing fine. I did start-ups in my career. Kool management is doing about as well as most I have seen in pharma/biotech. I give them a congratulations and thank you as a shareholder. Many did worse this quarter!